EZZ Life Science Holdings Ltd. (AU:EZZ)
ASX:EZZ
Want to see AU:EZZ full AI Analyst Report?
Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
Select Model
Select Model
Rating:61Neutral
Price Target:
AU$0.63
▼(-56.34% Downside)
Action:ReiteratedDate:05/08/26
The score is primarily supported by strong profitability metrics and a low-leverage, solid balance sheet. This is offset by weak technicals (price below all key moving averages with negative MACD) and growth/cash-flow concerns (recent revenue decline and weaker cash conversion), while the high dividend yield provides partial valuation support despite a negative P/E.
Positive Factors
High Gross & Net Margins
Sustained gross margins above 70% and a net margin near 10% indicate durable unit economics and pricing power in supplements. High margins provide a structural cushion against input or distribution cost swings, enabling reinvestment in marketing, product development, and supporting dividends over multiple quarters.
Negative Factors
Declining Revenue Trend
A persistent top-line decline weakens scale advantages and can erode margin resilience despite high unit margins. Falling revenue constrains reinvestment, reduces ability to spread fixed costs, and raises the risk that pricing power or market share is deteriorating in core geographies over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross & Net Margins
Sustained gross margins above 70% and a net margin near 10% indicate durable unit economics and pricing power in supplements. High margins provide a structural cushion against input or distribution cost swings, enabling reinvestment in marketing, product development, and supporting dividends over multiple quarters.
Read all positive factors
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.40M
Dividend Yield2.81%
Average Volume (3M)49.70K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-18.17%
EPS Growth-70.18%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.57
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited provides skin care and consumer health products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned products. It is involved in ...
How the Company Makes Money
EZZ primarily makes money by selling health and nutritional supplement products (revenue recognized from product sales). Its key revenue stream is the wholesale and retail distribution of its branded supplements to customers via online marketplace...
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.40M | 66.87M | 66.44M | 37.14M | 15.02M | 22.29M |
| Gross Profit | 41.95M | 49.72M | 50.95M | 27.20M | 7.51M | 12.46M |
| EBITDA | 5.42M | 11.10M | 10.38M | 5.09M | 1.90M | 2.87M |
| Net Income | 2.89M | 6.73M | 6.96M | 3.63M | 1.31M | 2.03M |
Balance Sheet | ||||||
| Total Assets | 32.60M | 33.96M | 25.55M | 17.64M | 14.27M | 12.04M |
| Cash, Cash Equivalents and Short-Term Investments | 13.47M | 20.85M | 19.02M | 13.83M | 10.46M | 8.85M |
| Total Debt | 123.86K | 304.49K | 123.86K | 478.59K | 104.57K | 79.01K |
| Total Liabilities | 4.80M | 5.87M | 4.23M | 3.06M | 2.88M | 1.93M |
| Stockholders Equity | 27.81M | 28.09M | 21.32M | 14.58M | 11.39M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.69M | 4.09M | 5.73M | 3.91M | 1.89M | 237.42K |
| Operating Cash Flow | -2.62M | 4.35M | 6.14M | 4.01M | 1.90M | 253.53K |
| Investing Cash Flow | -862.95K | -546.93K | -441.17K | -101.78K | -13.18K | -16.12K |
| Financing Cash Flow | -2.20M | -2.17M | -582.45K | -761.72K | -277.36K | 5.44M |
EZZ Life Science Holdings Ltd. Technical Analysis
Negative
1.45
Price Trends
1.15
Negative
1.45
Negative
1.91
Negative
Market Momentum
-0.09
Negative
30.29
Neutral
8.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 1.45 is above the 20-day moving average (MA) of 0.84, above the 50-day MA of 1.15, and below the 200-day MA of 1.91, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 30.29 is Neutral, neither overbought nor oversold. The STOCH value of 8.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.
EZZ Life Science Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$29.40M | -25.86 | 10.35% | 2.81% | -18.17% | -70.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$66.70M | -3.83 | -24.81% | ― | ― | 26.64% | |
44 Neutral | AU$91.87M | -14.80 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$119.63M | -2.12 | -30.19% | ― | ― | 62.50% | |
41 Neutral | AU$144.59M | -2.84 | 279.21% | ― | ― | -37.23% | |
40 Underperform | AU$43.66M | -0.70 | -134.65% | ― | ― | 62.72% |
* Healthcare Sector Average
AU:EZZ
EZZ Life Science Holdings Ltd.
0.63
-0.79
-55.95%
AU:ATX
Amplia Therapeutics
0.13
0.08
136.36%
AU:IMU
Imugene
0.11
-0.64
-85.96%
AU:ATH
Alterity Therapeutics
0.01
>-0.01
-8.33%
AU:RCE
Recce Pharmaceuticals Ltd.
0.50
0.20
66.67%
AU:ALA
Arovella Therapeutics Limited
0.08
>-0.01
-9.52%
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Builds Strategic Partnerships as Softer Demand Weighs on Quarterly Cash Flow
Apr 30, 2026
EZZ Life Science reported Q3 FY26 customer receipts of $8.85 million, a 25% decline amid softer demand on major e-commerce platforms, leading to a net operating cash outflow of $3.2 million. The company ended the quarter with $9.96 million in cash...
EZZ Life Science Swings to Half-Year Loss as Revenue Falls but Balance Sheet Stays Solid
Feb 27, 2026
EZZ Life Science Holdings Limited reported an 18.07% decline in revenue to $24.8 million for the half-year to 31 December 2025 and swung from a prior profit to a net loss after tax of $641,298. Despite this, the group generated normalised EBITDA o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.